SMC^® Human SARS-CoV-2 S1 IgA Kit

Assay mechanism includes proprietary elution and digital molecular counting steps that enable the SMC^® SARS-CoV-2 S1 IgA kit to detect antigen specific IgA in human serum and plasma at much lower levels compared to traditional immunoassays.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

The Single Molecule Counting (SMC^®) Human SARS-CoV-2 S1 IgA kit uses a fluorescent sandwich immunoassay technique to measure SARS-CoV-2 S1 IgA in Human EDTA Plasma and Serum samples. A Human SARS-CoV-2 S1 capture protein has been pre-coated onto paramagnetic microparticles (beads). The user pipettes beads and samples into uncoated microplate wells. During incubation, the SARS-CoV-2 S1 IgA present in the sample binds to the capture protein on the coated beads. Unbound molecules are washed away during the subsequent wash steps. Fluor-labeled detection antibody is added to each well and incubated. This detection antibody recognizes and binds to IgA antibodies against SARS-CoV-2 S1 that have been captured onto the beads, thus completing the immunosandwich. Elution buffer is then added and incubated. The elution buffer dissociates the bound protein sandwich from the beads surface releasing the labeled antibodies. These antibodies are separated during transfer to a final microplate. The plate is loaded into the SMCxPRO^® System where the labeled molecules are detected and counted. The number of fluor-labeled detection antibodies counted is directly proportional to the amount of SARS-CoV-2 S1 IgA present in the sample when captured. The amount of SARS-CoV-2 S1 IgA in unknown samples is qualitatively assessed in raw signal to determine COVID-19 infection when compared against known negative samples.

This new kit has the following features:

• For use with the state of the art SMCxPRO^® Ultrasensitive Immunoassay System
• Qualitative assay; no standard curve
• For Research Use Only. Not For Use In Diagnostic Procedures
• Detects SARS-CoV-2 S1 specific IgA antibody as early as 3 days after PCR positive result
• Requires as little as 2μL of human serum and plasma sample (1:50 recommended dilution)
• Fast assay protocol (one hour capture, 30 minute detection steps)

Research Category:
Inflammation & Immunology, Immune Response, Infectious Diseases, Isotyping

Research Sub-Category:
Inflammatory Disease, Immune Response, Virology, Infectious Diseases - Viral, Immunoglobulins & Immunology

96 well assay

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany